Live feed08:00:00·5mPRReleasevia QuantisnowEnhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
